ALCEDIAG and Merck announce today that they will work together using Alcediag’s RNA editing platform for preclinical drug discovery activities.
Alcediag has been at the forefront of RNA editing technology and has developed a biomarker discovery and RNA editing platform that is used to serve the company’s R&D needs, as well as those of third parties. The company currently uses this platform to develop groundbreaking solutions for mental health diagnostics. However, this platform can be used for a large range of pathologies including neurodegenerative disorders, inflammatory diseases, and cancers.
Thanks to its game-changing technology the company’s solutions support the entire patient management chain from initial diagnostics to monitoring outcomes.
This technology and platform will now be used by Merck to deliver transformative medicines that make a real difference in patients' lives.
Alcediag is a precision diagnostics company focusing primarily on mental health. It develops and commercializes blood-based diagnostic solutions for mental health. Based on its expertise and experience, Alcediag developed a platform harnessing cutting-edge molecular biology and Artificial Intelligence to discover new biomarkers based on RNA editing. The company uses this platform for its own products and services and collaborates with other entities to discover biomarkers for other pathologies. Alcediag is a subsidiary of Alcen.
Headquartered in France, Alcen is an industrial group that operates in 5 fields: Defense & Security, Energy, Medical & Healthcare, Aeronautics & Space, and Large Scientific Instruments. It developed a particularly extensive in-house technological base that works closely with research centers, systematically transfers technological developments and feedback from one field to the others.
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.